$MTEM
Molecular Templates, Inc.

2017 Q3 Form 10-Q Financial Statement

#000156459017023807 Filed on November 14, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q4 2016 Q3
Revenue $648.0K $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.000M $1.950M $810.0K
YoY Change 393.83% -13.33% -65.82%
% of Gross Profit
Research & Development $2.522M $3.010M $2.271M
YoY Change 11.05% -73.53% -71.9%
% of Gross Profit
Depreciation & Amortization $30.00K $20.00K -$260.0K
YoY Change -111.54% -92.0% -204.0%
% of Gross Profit
Operating Expenses $6.518M $4.960M $3.081M
YoY Change 111.55% -63.58% -70.53%
Operating Profit -$5.870M -$3.081M
YoY Change 90.52%
Interest Expense $107.0K $40.00K $6.000K
YoY Change 1683.33% 33.33% -80.0%
% of Operating Profit
Other Income/Expense, Net -$107.0K $1.250M -$118.0K
YoY Change -9.32% -92.83% -136.88%
Pretax Income -$10.97M -$3.680M -$3.190M
YoY Change 243.89% -105.28% -50.39%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.97M -$3.682M -$3.192M
YoY Change 243.58% -105.28% -50.37%
Net Earnings / Revenue -1692.44%
Basic Earnings Per Share -$0.05
Diluted Earnings Per Share -$611.8K -$0.05 -$490.8K
COMMON SHARES
Basic Shares Outstanding 71.56M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q3 2016 Q4 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $68.20M $1.700M $28.10M
YoY Change 142.7% -96.51% -50.18%
Cash & Equivalents $68.20M $1.716M $1.632M
Short-Term Investments $13.00M
Other Short-Term Assets $1.400M $7.000K $1.000M
YoY Change 40.0% -99.73% -44.44%
Inventory
Prepaid Expenses $120.0K
Receivables $38.00K $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $69.58M $1.843M $29.50M
YoY Change 135.87% -96.53% -52.57%
LONG-TERM ASSETS
Property, Plant & Equipment $963.0K $334.0K $200.0K
YoY Change 381.5% 0.3% -50.0%
Goodwill $3.314M $0.00
YoY Change
Intangibles $1.321M $921.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Assets $32.92M $22.44M $200.0K
YoY Change 16359.0% 4396.99% -88.89%
TOTAL ASSETS
Total Short-Term Assets $69.58M $1.843M $29.50M
Total Long-Term Assets $32.92M $22.44M $200.0K
Total Assets $102.5M $24.28M $29.70M
YoY Change 245.12% -54.75% -53.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.800M $822.0K $700.0K
YoY Change 442.86% 13.38% 75.0%
Accrued Expenses $1.500M $888.0K $3.000M
YoY Change -50.0% -72.84% -67.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $7.300M $0.00
YoY Change
Long-Term Debt Due $2.348M $2.400M
YoY Change
Total Short-Term Liabilities $11.31M $13.77M $3.700M
YoY Change 205.59% 27.12% -84.77%
LONG-TERM LIABILITIES
Long-Term Debt $1.734M $3.165M $0.00
YoY Change
Other Long-Term Liabilities $1.600M $53.00K $3.100M
YoY Change -48.39% -97.35% -95.61%
Total Long-Term Liabilities $1.734M $3.218M $3.100M
YoY Change -44.06% 60.9% -95.61%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.31M $13.77M $3.700M
Total Long-Term Liabilities $1.734M $3.218M $3.100M
Total Liabilities $14.64M $17.03M $6.800M
YoY Change 115.26% 32.82% -92.83%
SHAREHOLDERS EQUITY
Retained Earnings -$57.56M -$40.37M
YoY Change -87.74%
Common Stock $145.5M $568.0K
YoY Change -99.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $87.90M -$39.81M $22.90M
YoY Change
Total Liabilities & Shareholders Equity $102.5M $3.098M $29.70M
YoY Change 245.24% -94.23% -53.59%

Cashflow Statement

Concept 2017 Q3 2016 Q4 2016 Q3
OPERATING ACTIVITIES
Net Income -$10.97M -$3.682M -$3.192M
YoY Change 243.58% -105.28% -50.37%
Depreciation, Depletion And Amortization $30.00K $20.00K -$260.0K
YoY Change -111.54% -92.0% -204.0%
Cash From Operating Activities -$4.060M -$830.0K $6.800M
YoY Change -159.71% -89.04% -163.43%
INVESTING ACTIVITIES
Capital Expenditures -$350.0K -$70.00K -$30.00K
YoY Change 1066.67% -40.0%
Acquisitions
YoY Change
Other Investing Activities $11.08M -$220.0K -$18.17M
YoY Change -160.98% -106.43% -233.7%
Cash From Investing Activities $10.73M -$290.0K -$18.20M
YoY Change -158.96% -108.48% -234.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 56.91M 1.210M 5.970M
YoY Change 853.27% 3933.33% 1655.88%
NET CHANGE
Cash From Operating Activities -4.060M -830.0K 6.800M
Cash From Investing Activities 10.73M -290.0K -18.20M
Cash From Financing Activities 56.91M 1.210M 5.970M
Net Change In Cash 63.58M 90.00K -5.430M
YoY Change -1270.9% -102.18% -272.38%
FREE CASH FLOW
Cash From Operating Activities -$4.060M -$830.0K $6.800M
Capital Expenditures -$350.0K -$70.00K -$30.00K
Free Cash Flow -$3.710M -$760.0K $6.830M
YoY Change -154.32% -89.96% -164.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6241947
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13765000
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11307000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
301275
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17183000
CY2017Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
38000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2017Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1363000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
127000
CY2017Q3 us-gaap Assets Current
AssetsCurrent
69582000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
1843000
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
963000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
334000
CY2017Q3 mtem In Process Research And Development
InProcessResearchAndDevelopment
27300000
CY2016Q4 mtem In Process Research And Development
InProcessResearchAndDevelopment
0
CY2017Q3 us-gaap Goodwill
Goodwill
3314000
CY2016Q4 us-gaap Goodwill
Goodwill
0
CY2017Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1321000
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
921000
CY2017Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
51000
CY2016Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
36000
CY2017Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0
CY2016Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
7315000
CY2017Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3585000
CY2017Q3 us-gaap Liabilities
Liabilities
14638000
CY2016Q4 us-gaap Liabilities
Liabilities
17032000
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9643000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2522000
CY2017Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2348000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1870000
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2400000
CY2016Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2017Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
60000
CY2016Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
53000
CY2017Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1392000
CY2016Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
49000
CY2017Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
145000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
0
CY2017Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1734000
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3165000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2016Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
25871000
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
27000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
145428000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
568000
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57556000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40373000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
87899000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-39805000
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
102537000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3098000
CY2017Q3 us-gaap Revenue From Grants
RevenueFromGrants
0
CY2016Q3 us-gaap Revenue From Grants
RevenueFromGrants
0
us-gaap Revenue From Grants
RevenueFromGrants
167000
us-gaap Revenue From Grants
RevenueFromGrants
1526000
CY2017Q3 us-gaap Revenues
Revenues
648000
CY2016Q3 us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
2575000
us-gaap Revenues
Revenues
1526000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2271000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4829000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7178000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3996000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
810000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8233000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2553000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
6518000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
3081000
us-gaap Operating Expenses
OperatingExpenses
13062000
us-gaap Operating Expenses
OperatingExpenses
9731000
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
35000
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
21000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1800000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
208000
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2685000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
3000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
4000000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5870000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
9000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-269000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
2000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
38000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-279000
CY2017Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-272000
CY2016Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-269000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2000
CY2017Q3 mtem Gain Loss On Conversion Of Notes
GainLossOnConversionOfNotes
-4719000
CY2016Q3 mtem Gain Loss On Conversion Of Notes
GainLossOnConversionOfNotes
0
mtem Gain Loss On Conversion Of Notes
GainLossOnConversionOfNotes
-4719000
mtem Gain Loss On Conversion Of Notes
GainLossOnConversionOfNotes
0
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3081000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10487000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8205000
CY2017Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1000
CY2016Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
6000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
18000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-107000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-118000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-752000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-10967000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-3192000
us-gaap Net Income Loss
NetIncomeLoss
-16225000
us-gaap Net Income Loss
NetIncomeLoss
-8464000
CY2017Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
138000
CY2016Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
393000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
958000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1179000
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3585000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-11.89
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.75
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-32.01
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17925585
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
301494
us-gaap Depreciation And Amortization
DepreciationAndAmortization
71000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
48000
us-gaap Share Based Compensation
ShareBasedCompensation
1430000
us-gaap Share Based Compensation
ShareBasedCompensation
85000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
282000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
250000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
280000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-101000
mtem Increase Decrease In Long Term Deposits
IncreaseDecreaseInLongTermDeposits
57000
mtem Increase Decrease In Long Term Deposits
IncreaseDecreaseInLongTermDeposits
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2618000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-26000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
57716000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1003000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
576000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-145000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2613000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1632000
us-gaap Interest Paid Net
InterestPaidNet
194000
us-gaap Interest Paid Net
InterestPaidNet
159000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
0
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1715000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-276000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6354000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8197000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
11216000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
10486000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
mtem Non Cash Capital Lease Additions To Fixed Assets
NonCashCapitalLeaseAdditionsToFixedAssets
57000
mtem Non Cash Capital Lease Additions To Fixed Assets
NonCashCapitalLeaseAdditionsToFixedAssets
50000
mtem Non Cash Fixed Asset Additions In Accounts Payable
NonCashFixedAssetAdditionsInAccountsPayable
274000
mtem Non Cash Fixed Asset Additions In Accounts Payable
NonCashFixedAssetAdditionsInAccountsPayable
0
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
287000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
us-gaap Payments For Capital Improvements
PaymentsForCapitalImprovements
82000
us-gaap Payments For Capital Improvements
PaymentsForCapitalImprovements
0
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
400000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
371000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
10447000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-396000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
3000000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
62372000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5980000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
66465000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4245000
mtem Non Cash Deemed Dividends On Preferred Stock
NonCashDeemedDividendsOnPreferredStock
958000
mtem Non Cash Deemed Dividends On Preferred Stock
NonCashDeemedDividendsOnPreferredStock
1179000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
26830000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
mtem Non Cash Warrants Issued With Debt
NonCashWarrantsIssuedWithDebt
0
mtem Non Cash Warrants Issued With Debt
NonCashWarrantsIssuedWithDebt
18000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-28226000
CY2016Q3 mtem Collaboration Revenues
CollaborationRevenues
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash and cash equivalents, investments, long term debt and accounts receivable.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash, cash equivalents and investments are invested in deposits with two major financial institutions in the United States. Deposits in these banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any realized losses on its deposits of cash, cash equivalents or investments.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company performs an ongoing credit evaluation of its strategic partners&#8217; financial conditions and generally does not require collateral to secure accounts receivable from its strategic partners. The Company&#8217;s exposure to credit risk associated with non-payment will be affected principally by conditions or occurrences within Takeda Pharmaceutical Company Ltd. (&#8220;Takeda&#8221;). Approximately 100% and 74% of total revenues for the three and nine months ended September 30, 2017, were derived from Takeda. There were no accounts receivable due from Takeda at December 31, 2016. See also Note 4, Research and Development Collaboration Agreement, regarding the collaboration agreements with Takeda.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug candidates developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or international regulatory agencies prior to commercial sales. There can be no assurance that the Company&#8217;s drug candidates will receive any of the required approvals or clearances. If the Company were to be denied approval or clearance or any such approval or clearance were to be delayed, it would have a material adverse impact on the Company.</p></div>
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
11-for-1 reverse stock split
CY2017Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
11
CY2017Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
0
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
5575000
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
1526000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-14201000
CY2017Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
0
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
0
mtem Collaboration Revenues
CollaborationRevenues
0
CY2017Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
0
CY2017Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2017Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
0
CY2017Q3 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2016Q3 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2017Q3 us-gaap Long Term Debt
LongTermDebt
4100000
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
5600000
CY2017Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
377273
CY2017Q3 mtem Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
712000
CY2016Q4 mtem Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
409000
CY2017Q3 us-gaap Interest Payable Current
InterestPayableCurrent
0
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
201000
CY2017Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
627000
CY2016Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
553000
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
103000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
26000
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
58000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
21000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
177000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1040000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1136000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1049000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1075000
CY2017Q3 mtem Operating Leases Future Minimum Payments Due In Six Years
OperatingLeasesFutureMinimumPaymentsDueInSixYears
718000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
486000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
5681000
CY2017Q3 us-gaap Capital Leases Future Minimum Payments Remainder Of Fiscal Year
CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear
12000
CY2017Q3 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
55000
CY2017Q3 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
33000
CY2017Q3 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
21000
CY2017Q3 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
121000
CY2017Q3 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
10000
CY2017Q3 us-gaap Capital Lease Obligations
CapitalLeaseObligations
111000
CY2017Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
9165279
CY2016Q4 mtem Temporary Equity Shares Issued And Outstanding
TemporaryEquitySharesIssuedAndOutstanding
9116405
CY2016Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
25871325
us-gaap Temporary Equity Accretion Of Dividends
TemporaryEquityAccretionOfDividends
958300
mtem Conversion Of Preferred Stock In To Common Stock Upon Merger
ConversionOfPreferredStockInToCommonStockUponMerger
-26829625
CY2017Q3 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0162
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0120
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y4M21D
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y3M
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.00
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.00
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.54
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.76
CY2017Q3 us-gaap Share Price
SharePrice
6.97
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.92
CY2016Q4 us-gaap Share Price
SharePrice
3.07
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1378000
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1430000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
85000
CY2017Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y9M18D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
941682
mtem Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger
963681
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
306627
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3335
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3094
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2205561
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2194308
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1870232
mtem Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice
33.62
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.40
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.23
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.84
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.96
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
16.01
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
17.75
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y1M10D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y29D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y1M6D
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6140000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
6131000
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5773000
CY2017Q3 mtem Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMerger
963681
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
us-gaap Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
0
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001564590-17-023807-index-headers.html Edgar Link pending
0001564590-17-023807-index.html Edgar Link pending
0001564590-17-023807.txt Edgar Link pending
0001564590-17-023807-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mtem-10q_20170930.htm Edgar Link pending
mtem-20170930.xml Edgar Link completed
mtem-20170930.xsd Edgar Link pending
mtem-20170930_cal.xml Edgar Link unprocessable
mtem-20170930_def.xml Edgar Link unprocessable
mtem-20170930_lab.xml Edgar Link unprocessable
mtem-20170930_pre.xml Edgar Link unprocessable
mtem-ex311_10.htm Edgar Link pending
mtem-ex312_11.htm Edgar Link pending
mtem-ex321_9.htm Edgar Link pending
mtem-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending